A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs LMB 763 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 15 Nov 2017 Planned patient number changed to 192.
- 12 Oct 2017 Planned End Date changed from 18 Oct 2018 to 1 Aug 2019.
- 12 Oct 2017 Planned primary completion date changed from 18 Oct 2018 to 1 Aug 2019.